Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s work centers on disease-modifying approaches aimed at what it identifies as key underlying biological drivers of neurodegeneration in Alzheimer’s patients. Acumen Pharmaceuticals’ lead drug candidate, ACU193, is a monoclonal antibody designed to selectively target amyloid-beta oligomers, a soluble and potentially toxic form of amyloid believed to play a central role in cognitive decline. The company is advancing ACU193 through clinical programs such as ALTITUDE-AD and INTERCEPT-AD, which evaluate safety, biomarker effects, and cognitive outcomes across different stages of the disease. Headquartered in Newton, Massachusetts and founded in 1996, Acumen Pharmaceuticals operates within the broader neuroscience and central nervous system therapeutics space, contributing to ongoing efforts to address a major unmet medical need in global healthcare markets.